BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 6809960)

  • 1. Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.
    Brosman SA
    J Urol; 1982 Jul; 128(1):27-30. PubMed ID: 6809960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.
    deKernion JB; Huang MY; Lindner A; Smith RB; Kaufman JJ
    J Urol; 1985 Apr; 133(4):598-601. PubMed ID: 3981707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
    Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
    Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
    J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guerin immunotherapy for bladder cancer.
    Lamm DL
    J Urol; 1985 Jul; 134(1):40-7. PubMed ID: 3892050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ.
    Brosman SA
    J Urol; 1985 Jul; 134(1):36-9. PubMed ID: 3892049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
    Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
    J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bladder cancer immunotherapy.
    Lamm DL; Thor DE; Stogdill VD; Radwin HM
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravesical instillation of bacillus Calmette-Guerin for superficial bladder carcinoma: study on significance of additional maintenance instillations of bacillus Calmette-Guerin].
    Yabusaki N; Komatsu H; Tago K; Yamada Y; Ueno A
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):290-6. PubMed ID: 1904120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
    Sarosdy MF; Lamm DL
    J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
    Soloway MS; Perry A
    J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PC; Oettgen HF; Melamed MR
    J Urol; 1986 Feb; 135(2):265-7. PubMed ID: 3511284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
    Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
    J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
    Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
    J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL; Thor DE; Harris SC; Reyna JA; Stogdill VD; Radwin HM
    J Urol; 1980 Jul; 124(1):38-40. PubMed ID: 6997513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.